Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117973163 | 11797316 | 3 | F | 20160628 | 20151203 | 20160705 | EXP | JP-SA-2015SA195257 | AVENTIS | KOAMI H, SAKAMOTO Y, FURUKAWA T, IMAHASE H, IWAMURA T, INOUE S. UTILITY OF ROTATIONAL THROMBOELASTOMETRY FOR THE DIAGNOSIS OF ASYMPTOMATIC HYPERFIBRINOLYSIS SECONDARY TO ANAPHYLAXIS. BLOOD COAGUL FIBRINOLYSIS. 2016;27(4):450-453. | 57.00 | YR | A | M | Y | 0.00000 | 20160705 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117973163 | 11797316 | 1 | PS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | INFUSION | UNK | 21759 | 126 | MG/M**2 | |||||||
| 117973163 | 11797316 | 2 | C | CAPECITABINE. | CAPECITABINE | 1 | Unknown | 0 | /cycle |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117973163 | 11797316 | 1 | Rectal cancer stage IV |
| 117973163 | 11797316 | 2 | Rectal cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117973163 | 11797316 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117973163 | 11797316 | Anaphylactic reaction | |
| 117973163 | 11797316 | Anaphylactic shock | |
| 117973163 | 11797316 | Blood fibrinogen increased | |
| 117973163 | 11797316 | Blood pressure decreased | |
| 117973163 | 11797316 | Dyspnoea | |
| 117973163 | 11797316 | Fibrin D dimer increased | |
| 117973163 | 11797316 | Fibrin degradation products increased | |
| 117973163 | 11797316 | Haemodynamic instability | |
| 117973163 | 11797316 | Heart rate increased | |
| 117973163 | 11797316 | Hyperfibrinolysis | |
| 117973163 | 11797316 | Loss of consciousness | |
| 117973163 | 11797316 | Oxygen saturation decreased | |
| 117973163 | 11797316 | Prothrombin time prolonged | |
| 117973163 | 11797316 | Pruritus generalised | |
| 117973163 | 11797316 | Respiratory failure | |
| 117973163 | 11797316 | Respiratory rate increased | |
| 117973163 | 11797316 | Skin lesion | |
| 117973163 | 11797316 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |